Navigation Links
IntegriChain Appoints John Bailye to Its Board of Directors
Date:6/2/2008

PRINCETON, N.J., June 2 /PRNewswire/ -- IntegriChain, Inc. today announced the appointment of industry veteran John Bailye to the Company's Board of Directors, further bolstering its position as a leader in the pharmaceutical information services industry.

Mr. Bailye, 54, recently retired from his position as Chairman & CEO of Dendrite International after Dendrite was acquired by French information provider Cegedim. Under Mr. Bailye's leadership, Dendrite, a pharmaceutical sales force automation system company, grew to more than 3500 employees, acquired 23 companies and generated $450 million in global sales revenue to become the leading SFA tool in the pharmaceutical industry. Throughout his career, Mr. Bailye has served on a number of not-for-profit organizations, including the New Jersey Technology Council where he was co-Founder and Board Member. Currently, Mr. Bailye is also a director, advisor and investor in Solar Centre LLC, a General Partner of the Roxiticus Life Sciences Fund.

Kevin Leininger, Chief Executive Officer of IntegriChain commented, "We are thrilled to have John join our Board of Directors. John is a seasoned executive and leader who brings a wealth of experience and proven track record in building a strong information services company in the pharmaceutical industry."

"IntegriChain has an innovative approach to helping pharmaceutical companies take more advantage of their channel data for commercial applications such as forecasting, demand validation and product launch," said Mr. Bailye. "I am excited by the sizeable potential IntegriChain represents and I look forward to leveraging my experience to help the Company expand its possibilities even further."

About IntegriChain

IntegriChain, Inc. is an information services company which provides data collection, integration, enrichment, analysis and reporting of sales and inventory activity for the pharmaceutical industry. IntegriChain enables manufacturers to improve sales performance and increase patient safety by maximizing transparency and accountability in the supply chain. IntegriChain's Enriched Channel Sales(TM) and advanced analytics are transforming the role of channel data within key pharmaceutical application areas including new product launch, sales forecasting, and demand analysis.


'/>"/>
SOURCE IntegriChain, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trius Appoints Paul Truex to Board of Directors
2. Pelikan Technologies Appoints Denny Ware to Board of Directors
3. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
4. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
5. Nventa Appoints Gordon H. Busenbark to Board of Directors
6. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
7. Informed Medical Communications Appoints New Chief Financial Officer
8. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
9. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
10. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
11. VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... ... a balanced, peaceful and healthy lifestyle, announced today the official launch of its much-anticipated ... frees the mind. , In development for over a year, the patented ...
(Date:1/17/2017)... ... January 17, 2017 , ... NeoTrident, a leading provider of ... performance management systems for high-consequence industries, announced today that they have entered into ... industry, organizations must pay much more attention to the quality of products than ...
(Date:1/17/2017)... 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... a global Phase 2b induction study in ulcerative ... alpha4beta7 integrin. The aim of this randomized, double-blind, ... safety/tolerability and efficacy of PTG-100 in approximately 240 ... active disease. "We are very ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... laws precedential publication its decision on the appeal filed by India-based Dishman Pharmaceutical ... breach of contract against DPCL and one of its Dishman Group’s 100% wholly ...
Breaking Biology Technology:
(Date:12/8/2016)... -- Market Research Future published a half cooked research report on ... and Service Market is expected to grow over the CAGR of ... ... Mobile Biometric Security and Service Market is increasing ... authentication and security from unwanted cyber threats. The increasing use of ...
(Date:12/7/2016)... BioCatch , the global leader in behavioral ... which grew to over 40 granted and pending patents. ... , , The Company,s ... " System, Device, and Method Estimating Force Applied to a Touch ... forego costly hardware components needed to estimate the force and pressure applied ...
(Date:12/6/2016)... WARSAW, Ind. , Dec. 6, 2016  Zimmer Biomet ... that it has priced an offering of €500.0 million principal ... €500.0 million principal amount of its 2.425% senior unsecured notes ... is expected to occur on December 13, 2016, subject to the ... on an annual basis. ...
Breaking Biology News(10 mins):